Want to join the conversation?
Mitra Ramgopal of Sidoti & Company asks about $CMN's Endoscopy performance and any benefits from the Custom Ultrasonics recall. CEO Andrew Krakauer said out of the 33.1% organic growth, about 5% came from Custom Ultrasonics. $CMN's organic growth ex Custom Ultrasonics was at 28.1%.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?